Literature DB >> 19067117

Study of conditioning regimens with or without high-dose radiotherapy before autologous stem cell transplantation for treating aggressive lymphoma.

Yi Niu1, Yuankai Shi2, Shengyu Zhou1, Feng Pan1, Shikai Wu1, Peng Liu1, Jiangliang Yang1, Xiaohong Han1, Xiaohui He1.   

Abstract

The aim and objective of the study is to compare the efficacy of conditioning regimens with or without high-dose radiotherapy for treating aggressive non-Hodgkin's lymphoma (NHL). Eighty-nine aggressive NHL patients who underwent high-dose therapy in combination with autologous stem cell transplantation (HDT/ASCT) between 1993 and 2006 were retrospectively studied. HDT was either high-dose chemotherapy alone (CT) or high-dose chemoradiotherapy (CRT). Overall, 37 patients in CT group and 52 in CRT group. The median radiotherapy DT in CRT group was 8 Gy. The median count of reinfused CD34+ cells was 6.26 x 10(6) and 22.16 x 10(6) cells/kg, respectively (p < 0.001). The median time of leukocyte engraftment was 11 days in CT group and 13 days in CRT group (p = 0.003), and the median platelet engraftment time was 12 days in CT group and 11 days in CRT group (p = 0.305). The median event-free survival (EFS) was 102 and 84 months in CT and CRT groups, respectively (p = 0.783), and the median overall survival (OS) was 102 and 121 months in CT and CRT groups, respectively (p = 0.857). Prolonged hospitalization favored EFS (p = 0.013) and OS (p = 0.011). In conclusion, when compared with CT, high-dose CRT does not improve prognosis.

Entities:  

Mesh:

Year:  2008        PMID: 19067117     DOI: 10.1007/s12185-008-0217-x

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  22 in total

1.  Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.

Authors:  Noel Milpied; Eric Deconinck; Fanny Gaillard; Vincent Delwail; Charles Foussard; Christian Berthou; Remy Gressin; Virginie Lucas; Philippe Colombat; Jean-Luc Harousseau
Journal:  N Engl J Med       Date:  2004-03-25       Impact factor: 91.245

2.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

Authors:  T Philip; C Guglielmi; A Hagenbeek; R Somers; H Van der Lelie; D Bron; P Sonneveld; C Gisselbrecht; J Y Cahn; J L Harousseau
Journal:  N Engl J Med       Date:  1995-12-07       Impact factor: 91.245

3.  Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study.

Authors:  H C Kluin-Nelemans; V Zagonel; A Anastasopoulou; D Bron; K J Roozendaal; E M Noordijk; H Musson; I Teodorovic; B Maes; A Carbone; P Carde; J Thomas
Journal:  J Natl Cancer Inst       Date:  2001-01-03       Impact factor: 13.506

4.  High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis.

Authors:  Alexander Greb; Julia Bohlius; Sven Trelle; Daniel Schiefer; Carmino A De Souza; Christian Gisselbrecht; Tanin Intragumtornchai; Ulrich Kaiser; Hanneke C Kluin-Nelemans; Maurizio Martelli; Noel Jean Milpied; Gino Santini; Leo F Verdonck; Umberto Vitolo; Guido Schwarzer; Andreas Engert
Journal:  Cancer Treat Rev       Date:  2007-04-02       Impact factor: 12.111

5.  High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis.

Authors:  T Kewalramani; A D Zelenetz; E E Hedrick; G B Donnelly; S Hunte; A C Priovolos; J Qin; N C Lyons; J Yahalom; S D Nimer; C H Moskowitz
Journal:  Blood       Date:  2000-10-01       Impact factor: 22.113

6.  Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies.

Authors:  S Park; P Brice; M E Noguerra; D Simon; P Rousselot; Y Kerneis; P Morel; J P Marolleau; C Gisselbrecht
Journal:  Bone Marrow Transplant       Date:  2000-08       Impact factor: 5.483

7.  Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.

Authors:  C Haioun; E Lepage; C Gisselbrecht; G Salles; B Coiffier; P Brice; A Bosly; P Morel; C Nouvel; H Tilly; P Lederlin; C Sebban; J Brière; P Gaulard; F Reyes
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

8.  The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group.

Authors:  J Blay; F Gomez; C Sebban; T Bachelot; P Biron; C Guglielmi; A Hagenbeek; R Somers; F Chauvin; T Philip
Journal:  Blood       Date:  1998-11-15       Impact factor: 22.113

9.  Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience.

Authors:  J Rodriguez; M D Caballero; A Gutierrez; C Solano; R Arranz; J J Lahuerta; J Sierra; M Gandarillas; J A Perez-Simon; J Zuazu; A Lopez-Guillermo; A Sureda; E Carreras; J Garcia-Laraña; J Marin; J C Garcia; A Fernandez De Sevilla; J Rifon; R Varela; I Jarque; C Albo; A Leon; J SanMiguel; E Conde
Journal:  Ann Oncol       Date:  2004-10       Impact factor: 32.976

10.  Malignant neoplasms following bone marrow transplantation.

Authors:  S Bhatia; N K Ramsay; M Steinbuch; K E Dusenbery; R S Shapiro; D J Weisdorf; L L Robison; J S Miller; J P Neglia
Journal:  Blood       Date:  1996-05-01       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.